Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 diluted* 
    $(2.98) 
    $(9.04) 
    $(18.48) 
    $(34.53)

    Weighted average number of shares used in calculating net loss per share, basic and diluted* 
     997,038  
     339,659  
    689,174  
     315,451 

    *
    Retroactively
    restated for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-2

INDAPTUS
THERAPEUTICS, INC.

Unaudited
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

    Shares*  
    Amount*  
    Capital*  
    deficit  
    Total 

    Common stock  
    Additional  paid in  
    Accumulated  

    Shares*  
    Amount*  
    Capital*  
    deficit  
    Total 

    Balance, January 1, 2024 
     300,037  
    $3,000  
    $57,490,654  
    $(45,417,156) 
    $12,076,498 
  
    Stock-based compensation 
     -  
     -  
     774,691  
     -  
     774,691 
  
    Issuance of shares of common stock, net of issuance costs 
     4,920  
     49  
     315,998  
     -  
     316,047 
  
    Net loss 
     -  
     -  
     -  
     (3,806,677) 
     (3,806,677)

    Balance, March 31, 2024 
     304,957  
    3,049  
    58,581,343  
    (49,223,833) 
    9,360,559 

    Stock-based compensation 
     -  
     -  
     782,852  
     -  
     782,852 
  
    Issuance of shares of common stock, net of issuance costs 
     505  
     5  
     38,059  
     -